MedTrace Logo

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

NCT02403284 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2024-07-22

No results posted yet for this study

Summary

In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.

Conditions

Interventions

DRUG

Liraglutide

Subcutaneous injection by patient

DRUG

Sugar Pill

Subcutaneous injection daily

Sponsors & Collaborators

Principal Investigators

  • Peter D Reaven, MD · Carl T. Hayden Medical Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2021-04-28
Completion
2023-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02403284 on ClinicalTrials.gov